Long-term overall survival in hepatocellular carcinoma with the anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) tremelimumab plus the anti-programmed death ligand-1 (PD-L1) durvalumab treatment is durable, according to an update of the HIMALAYA trial.
In the multinational trial, which evaluated the combination of checkpoint inhibitors as first-line therapy in HCC, 1,171 patients with unresectable and previously untreated HCC were randomly assigned to receive the combination of durvalumab